Aleafia Health (TSX: AH) has finally entered the cannabis 2.0 market. The company issued a short press release this morning, identifying that it has launched the first of its second generation products via the release of 510 vape cartridges.
While the headline for the release identified that “unique formulations” were featured within the vape cartridges, no further details were provided. In fact, its unclear how many product varieties were even released, despite the company making an announcement in relation to the release. Instead, the company elected to elaborate on how this was an, “important milestone which represents just the first step in our entering the adult-use market in a meaningful way.”
The vape cartridges are said to be sold under the Symbl brand for adult-use variants, while its medical product will be sold under the Emblem brand. The distillate contained within is said to be extracted via C02 methods, with a custom blend of “botanically sourced terpenes.”
The company also offered up an update on its other second generation products that are currently in production. Sublingual strips are said to be under full production and packaging currently, with a near term launch planned. Production of edibles has also begun, however no timeline was provided to the market on products being released. Finally, the company has identified that it has obtained new cultivars for its dried flower offering, which are currently in production.
Aleafia Health last traded at $0.46 on the TSX.
Information for this briefing was found via Sedar and Aleafia Health. The author has no affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
Why Public Cannabis CFOs Need to Breakdown and Segment Their Accounts Receivables
Limited Disclosures Risk Signaling Poor Financial Health to Analysts and Investors The ‘accounts receivable to...